2 companies
UCB
Market Cap: €48.3b
A biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.
UCB
€254.20
7D
0.8%
1Y
34.2%
argenx
Market Cap: €42.7b
A commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
ARGX
€697.00
7D
1.6%
1Y
6.6%